Antianxiety effect of cannabidiol in the elevated plus-maze

Psychopharmacology (Berl). 1990;100(4):558-9. doi: 10.1007/BF02244012.


In order to assess the presence of anxiolytic properties in cannabidiol (CBD) the drug was tested in an elevated plus-maze model of anxiety, in rats. Doses of 2.5, 5.0 and 10.0 mg/kg significantly increased the entry ratio (open/total number of entries), an anxiolytic-like effect. CBD at a dose of 20.0 mg/kg was no longer effective. None of the doses of CBD used changed total number of entries, a measure of total exploratory activity. Diazepam (2.0 mg/kg) also caused an anxiolytic-like effect in this model. These results indicate that CBD causes a selective anxiolytic effect in the elevated plus-maze, within a limited range of doses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Anxiety Agents*
  • Cannabidiol / pharmacology*
  • Cannabinoids / pharmacology*
  • Diazepam
  • Dose-Response Relationship, Drug
  • Injections, Intraperitoneal
  • Male
  • Rats
  • Rats, Inbred Strains


  • Anti-Anxiety Agents
  • Cannabinoids
  • Cannabidiol
  • Diazepam